FI3716998T3 - A1at akuutin käänteishyljintätaudin puhkeamisriskin vähentämiseksi hematopoieettisten solujen siirron jälkeen - Google Patents

A1at akuutin käänteishyljintätaudin puhkeamisriskin vähentämiseksi hematopoieettisten solujen siirron jälkeen Download PDF

Info

Publication number
FI3716998T3
FI3716998T3 FIEP18821851.5T FI18821851T FI3716998T3 FI 3716998 T3 FI3716998 T3 FI 3716998T3 FI 18821851 T FI18821851 T FI 18821851T FI 3716998 T3 FI3716998 T3 FI 3716998T3
Authority
FI
Finland
Prior art keywords
subject
a1at
antitrypsin
alpha
use according
Prior art date
Application number
FIEP18821851.5T
Other languages
English (en)
Finnish (fi)
Inventor
Marc Uknis
Christine Voigt
Gautam Baheti
John Roberts
Original Assignee
Csl Behring Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Llc filed Critical Csl Behring Llc
Application granted granted Critical
Publication of FI3716998T3 publication Critical patent/FI3716998T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
FIEP18821851.5T 2017-12-01 2018-11-30 A1at akuutin käänteishyljintätaudin puhkeamisriskin vähentämiseksi hematopoieettisten solujen siirron jälkeen FI3716998T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762593446P 2017-12-01 2017-12-01
US201862729376P 2018-09-10 2018-09-10
PCT/US2018/063179 WO2019108865A1 (en) 2017-12-01 2018-11-30 Methods for reducing risk of onset of acute graft versus host disease after hematopoeitic cell transplantation

Publications (1)

Publication Number Publication Date
FI3716998T3 true FI3716998T3 (fi) 2024-04-16

Family

ID=64734181

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP18821851.5T FI3716998T3 (fi) 2017-12-01 2018-11-30 A1at akuutin käänteishyljintätaudin puhkeamisriskin vähentämiseksi hematopoieettisten solujen siirron jälkeen

Country Status (13)

Country Link
US (2) US11857610B2 (https=)
EP (2) EP4321220B1 (https=)
JP (2) JP2021505545A (https=)
AU (1) AU2018374285B2 (https=)
DK (1) DK3716998T3 (https=)
ES (2) ES2975208T3 (https=)
FI (1) FI3716998T3 (https=)
HR (1) HRP20240475T8 (https=)
HU (1) HUE066011T2 (https=)
PL (1) PL3716998T3 (https=)
PT (1) PT3716998T (https=)
SI (1) SI3716998T1 (https=)
WO (1) WO2019108865A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021028927A1 (en) * 2019-08-15 2021-02-18 Kamada Ltd Combination of alpha-1-antitrypsin and steroids and uses therefor
WO2023056075A1 (en) * 2021-10-01 2023-04-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for reduced toxicity in transplantation using janus kinase (jak) inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457070B2 (en) * 2005-06-07 2016-10-04 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease
US8715649B2 (en) 2005-06-07 2014-05-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity
US20090118162A1 (en) 2005-06-07 2009-05-07 Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival
CN101341254A (zh) * 2005-12-24 2009-01-07 蒂加斯克乳制品研究中心 反-10，顺-12十八碳二烯酸的生产方法
US20090028832A1 (en) * 2006-08-10 2009-01-29 Chung Leland F Compositions and methods for targeted tumor therapy
CA2798518A1 (en) * 2010-05-17 2011-11-24 Cebix, Inc. Pegylated c-peptide
EP3628327A1 (en) * 2011-06-24 2020-04-01 The Regents of the University of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
US10400029B2 (en) * 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
CN110551223A (zh) 2011-06-28 2019-12-10 英伊布里克斯有限合伙公司 丝氨酸蛋白酶抑制蛋白融合多肽及其使用方法
AU2013202648B2 (en) 2012-01-10 2016-05-19 Konkuk University Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
ES2799153T3 (es) 2013-03-29 2020-12-15 Univ Colorado Regents Alfa 1 antitripsina para uso en la preparación de un sujeto para trasplante
WO2017117558A1 (en) 2015-12-31 2017-07-06 The Regents Of The University Of Colorado, A Body Corporate Methods and uses for alpha-1 antitrypsin or recombinant forms thereof, on steroid-refractory graft versus host disease involving gastrointestinal complications

Also Published As

Publication number Publication date
HRP20240475T8 (hr) 2024-08-02
SI3716998T1 (sl) 2024-05-31
EP3716998B1 (en) 2024-01-10
PT3716998T (pt) 2024-04-09
EP4321220B1 (en) 2025-10-29
DK3716998T3 (da) 2024-04-02
JP2021505545A (ja) 2021-02-18
JP2024001191A (ja) 2024-01-09
PL3716998T3 (pl) 2024-06-24
US20210008182A1 (en) 2021-01-14
US20240238395A1 (en) 2024-07-18
US11857610B2 (en) 2024-01-02
HUE066011T2 (hu) 2024-07-28
AU2018374285B2 (en) 2024-06-27
ES3059603T3 (en) 2026-03-23
HRP20240475T1 (hr) 2024-07-05
AU2018374285A1 (en) 2020-07-02
WO2019108865A1 (en) 2019-06-06
EP4321220A3 (en) 2024-03-20
EP4321220A2 (en) 2024-02-14
EP3716998A1 (en) 2020-10-07
ES2975208T3 (es) 2024-07-04

Similar Documents

Publication Publication Date Title
Ozdemir et al. Graft failure after allogeneic hematopoietic stem cell transplantation
Jang et al. Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia
Fang et al. Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease
Lu et al. Unmanipulated haploidentical hematopoietic stem cell transplantation achieved outcomes comparable with matched unrelated donor transplantation in young acquired severe aplastic anemia
Bonfim et al. Haploidentical bone marrow transplantation with post-transplant cyclophosphamide for children and adolescents with Fanconi anemia
Jaiswal et al. CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: a pilot study
Aliabadi et al. Induction therapy in heart transplantation: where are we now?
Ayas et al. Successful outcome in patients with Fanconi anemia undergoing T cell-replete mismatched related donor hematopoietic cell transplantation using reduced-dose cyclophosphamide post-transplantation
JP2015524415A5 (https=)
Kornblit et al. A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation
Sadeghi et al. Long-term follow-up of a pilot study using placenta-derived decidua stromal cells for severe acute graft-versus-host disease
FI3716998T3 (fi) A1at akuutin käänteishyljintätaudin puhkeamisriskin vähentämiseksi hematopoieettisten solujen siirron jälkeen
Krasowska-Kwiecien et al. Mesenchymal stem cells as a salvage treatment for severe refractory graft-vs-host disease in children after bone marrow transplantation
Fang et al. Anti-CD45RB antibody therapy attenuates renal ischemia-reperfusion injury by inducing regulatory B cells
Ramanathan et al. CD3+ TCRαβ/CD19+-depleted mismatched family or unrelated donor salvage stem cell transplantation for graft dysfunction in inborn errors of immunity
Ghez et al. Rapamycin for refractory acute graft-versus-host disease
Wang et al. Influence of pharmacological immunomodulatory agents on CD4+ CD25highFoxP3+ T regulatory cells in humans
Sageshima et al. Prolonged lymphocyte depletion by single-dose rabbit anti-thymocyte globulin and alemtuzumab in kidney transplantation
Gómez-Almaguer et al. Antibodies in the treatment of aplastic anemia
Hamad et al. Outcomes of hematopoietic cell transplantation in adult patients with acquired aplastic anemia using intermediate-dose alemtuzumab-based conditioning
Annaloro et al. Autologous hematopoietic stem cell transplantation in autoimmune diseases
Sanz et al. Single-unit umbilical cord blood transplantation from unrelated donors in adult patients with chronic myelogenous leukemia
Topcuoglu et al. Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients
Lu et al. Haploidentical hematopoietic stem cell transplantation following myeloablative conditioning regimens in hematologic diseases with G-CSF-mobilized peripheral blood stem cells grafts without T cell depletion: a single center report of 38 cases
Remuzzi Transplant tolerance: progress and challenges